[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fuYwZR7zF3yTqPwjyq37nVuaZl8DORepyRtAOjXOl94M":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":60,"rows":67},"University Ghent",[4],339,false,68,5,108980,6,307,[14,17,20,22,25,27,29,32],{"name":15,"count":16},"Suicidal Ideation",14,{"name":18,"count":19},"Healthy",10,{"name":21,"count":19},"Suicide",{"name":23,"count":24},"Neck Pain",9,{"name":26,"count":24},"Pressure Ulcer",{"name":28,"count":24},"Suicide Prevention",{"name":30,"count":31},"Physical Activity",8,{"name":33,"count":11},"Developmental Coordination Disorder",[35,40,45,50,55],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT05768477","Different Treatments in Chronic Pain Patients.","2026-04","Baxter therapy",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT07134790","Maternal Probiotic Intervention to Improve Gut Health - Trial II - Burkina Faso (MPIGH-II)","2026-07-07","VE818",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT06832514","Investigating Gender and Sex Differences in Immune Responses Through Vaccination of Transgender and Cisgender Persons","2026-07-31","Serogroup B meningococal vaccine",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT06152497","The Role of Histamine in Muscle Protein Synthesis Following Resistance Training","2026-12-31","H1 blockade: Telfast: 180mg Fexofenadine",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT03299179","The Effects of the Female Hormones on Cerebral Perfusion","2027-12-31","Blood sample",[61,62,63,64,65,66],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[68,95,118,136,159,180,203,230,257,275,301,319,346,364,394,412,430,448,466,493,518,543,574,598,616,640,665,690,708,736,754,772,797,822,847,870,909,934,959,985,1003,1021,1047,1065,1089,1116,1134,1161],{"intervention":49,"totalTrials":69,"cells":70},1,{"EARLY_PHASE1":71,"PHASE1":74,"PHASE2":76,"PHASE3":78,"PHASE4":80,"NA":93},{"trials":72,"activeCount":73},[],0,{"trials":75,"activeCount":73},[],{"trials":77,"activeCount":73},[],{"trials":79,"activeCount":73},[],{"trials":81,"activeCount":69,"soonestReadout":48},[82],{"nctId":46,"briefTitle":47,"status":83,"phases":84,"primaryCompletion":48,"completion":53,"start":85,"enrollment":86,"conditions":87,"interventions":92},"RECRUITING",[65],"2025-01-31",250,[88,89,90,91],"Meningococcal Meningitis, Serogroup B","Transgender Persons","Sex Differences in Immune Response","Vaccination",[49],{"trials":94,"activeCount":73},[],{"intervention":44,"totalTrials":69,"cells":96},{"EARLY_PHASE1":97,"PHASE1":99,"PHASE2":101,"PHASE3":112,"PHASE4":114,"NA":116},{"trials":98,"activeCount":73},[],{"trials":100,"activeCount":73},[],{"trials":102,"activeCount":69,"soonestReadout":43},[103],{"nctId":41,"briefTitle":42,"status":83,"phases":104,"primaryCompletion":43,"completion":105,"start":106,"enrollment":107,"conditions":108,"interventions":110},[63],"2027-06-07","2025-07-30",144,[109],"Environmental Enteric Dysfunction (EED)",[44,111],"Oral Vancomycin",{"trials":113,"activeCount":73},[],{"trials":115,"activeCount":73},[],{"trials":117,"activeCount":73},[],{"intervention":111,"totalTrials":69,"cells":119},{"EARLY_PHASE1":120,"PHASE1":122,"PHASE2":124,"PHASE3":130,"PHASE4":132,"NA":134},{"trials":121,"activeCount":73},[],{"trials":123,"activeCount":73},[],{"trials":125,"activeCount":69,"soonestReadout":43},[126],{"nctId":41,"briefTitle":42,"status":83,"phases":127,"primaryCompletion":43,"completion":105,"start":106,"enrollment":107,"conditions":128,"interventions":129},[63],[109],[44,111],{"trials":131,"activeCount":73},[],{"trials":133,"activeCount":73},[],{"trials":135,"activeCount":73},[],{"intervention":59,"totalTrials":69,"cells":137},{"EARLY_PHASE1":138,"PHASE1":140,"PHASE2":142,"PHASE3":144,"PHASE4":146,"NA":148},{"trials":139,"activeCount":73},[],{"trials":141,"activeCount":73},[],{"trials":143,"activeCount":73},[],{"trials":145,"activeCount":73},[],{"trials":147,"activeCount":73},[],{"trials":149,"activeCount":69,"soonestReadout":58},[150],{"nctId":56,"briefTitle":57,"status":83,"phases":151,"primaryCompletion":58,"completion":58,"start":152,"enrollment":153,"conditions":154,"interventions":158},[],"2016-10-03",62,[155,156,157],"Cerebral Perfusion","Contraception","Menstrual Cycle",[59],{"intervention":54,"totalTrials":69,"cells":160},{"EARLY_PHASE1":161,"PHASE1":163,"PHASE2":165,"PHASE3":167,"PHASE4":169,"NA":171},{"trials":162,"activeCount":73},[],{"trials":164,"activeCount":73},[],{"trials":166,"activeCount":73},[],{"trials":168,"activeCount":73},[],{"trials":170,"activeCount":73},[],{"trials":172,"activeCount":69,"soonestReadout":53},[173],{"nctId":51,"briefTitle":52,"status":83,"phases":174,"primaryCompletion":53,"completion":53,"start":175,"enrollment":176,"conditions":177,"interventions":179},[66],"2023-09-01",50,[178],"Histamine",[54],{"intervention":39,"totalTrials":69,"cells":181},{"EARLY_PHASE1":182,"PHASE1":184,"PHASE2":186,"PHASE3":188,"PHASE4":190,"NA":192},{"trials":183,"activeCount":73},[],{"trials":185,"activeCount":73},[],{"trials":187,"activeCount":73},[],{"trials":189,"activeCount":73},[],{"trials":191,"activeCount":73},[],{"trials":193,"activeCount":69,"soonestReadout":38},[194],{"nctId":36,"briefTitle":37,"status":83,"phases":195,"primaryCompletion":38,"completion":196,"start":197,"enrollment":198,"conditions":199,"interventions":202},[],"2027-06-30","2023-04-06",1000,[200,201],"Chronic Pain","Nociplastic Pain",[39],{"intervention":204,"totalTrials":69,"cells":205},"desmopressin",{"EARLY_PHASE1":206,"PHASE1":208,"PHASE2":210,"PHASE3":212,"PHASE4":214,"NA":228},{"trials":207,"activeCount":73},[],{"trials":209,"activeCount":73},[],{"trials":211,"activeCount":73},[],{"trials":213,"activeCount":73},[],{"trials":215,"activeCount":73},[216],{"nctId":217,"briefTitle":218,"status":219,"phases":220,"primaryCompletion":221,"completion":222,"start":223,"enrollment":224,"conditions":225,"interventions":227},"NCT02584231","Pharmacokinetics and Pharmacodynamics of Desmopressin Oral Lyophilisate Formulation in the Paediatric Population","COMPLETED",[65],"2018-03-19","2019-02-01","2015-09-09",25,[226],"Monosymptomatic Nocturnal Enuresis",[204],{"trials":229,"activeCount":73},[],{"intervention":231,"totalTrials":69,"cells":232},"Totalfill",{"EARLY_PHASE1":233,"PHASE1":235,"PHASE2":237,"PHASE3":239,"PHASE4":241,"NA":255},{"trials":234,"activeCount":73},[],{"trials":236,"activeCount":73},[],{"trials":238,"activeCount":73},[],{"trials":240,"activeCount":73},[],{"trials":242,"activeCount":73},[243],{"nctId":244,"briefTitle":245,"status":219,"phases":246,"primaryCompletion":247,"completion":248,"start":249,"enrollment":250,"conditions":251,"interventions":253},"NCT05149651","Efficacy of Totalfill® and ProRoot MTA® as Pulpotomy Agent in Primary Molars",[65],"2018-12-31","2020-12-31","2017-01-01",36,[252],"Extensively Decayed Primary Molars",[231,254],"MTA",{"trials":256,"activeCount":73},[],{"intervention":254,"totalTrials":69,"cells":258},{"EARLY_PHASE1":259,"PHASE1":261,"PHASE2":263,"PHASE3":265,"PHASE4":267,"NA":273},{"trials":260,"activeCount":73},[],{"trials":262,"activeCount":73},[],{"trials":264,"activeCount":73},[],{"trials":266,"activeCount":73},[],{"trials":268,"activeCount":73},[269],{"nctId":244,"briefTitle":245,"status":219,"phases":270,"primaryCompletion":247,"completion":248,"start":249,"enrollment":250,"conditions":271,"interventions":272},[65],[252],[231,254],{"trials":274,"activeCount":73},[],{"intervention":276,"totalTrials":69,"cells":277},"ACTIVA™ BioACTIVE",{"EARLY_PHASE1":278,"PHASE1":280,"PHASE2":282,"PHASE3":284,"PHASE4":286,"NA":299},{"trials":279,"activeCount":73},[],{"trials":281,"activeCount":73},[],{"trials":283,"activeCount":73},[],{"trials":285,"activeCount":73},[],{"trials":287,"activeCount":73},[288],{"nctId":289,"briefTitle":290,"status":219,"phases":291,"primaryCompletion":292,"completion":292,"start":293,"enrollment":294,"conditions":295,"interventions":297},"NCT03516838","Comparison of ACTIVA BioACTIVE Versus Compomer in Restoring Dental Decay in Primary Molar Teeth",[65],"2018-12","2017-01",35,[296],"Dental Caries in Children",[276,298],"Compomer",{"trials":300,"activeCount":73},[],{"intervention":298,"totalTrials":69,"cells":302},{"EARLY_PHASE1":303,"PHASE1":305,"PHASE2":307,"PHASE3":309,"PHASE4":311,"NA":317},{"trials":304,"activeCount":73},[],{"trials":306,"activeCount":73},[],{"trials":308,"activeCount":73},[],{"trials":310,"activeCount":73},[],{"trials":312,"activeCount":73},[313],{"nctId":289,"briefTitle":290,"status":219,"phases":314,"primaryCompletion":292,"completion":292,"start":293,"enrollment":294,"conditions":315,"interventions":316},[65],[296],[276,298],{"trials":318,"activeCount":73},[],{"intervention":320,"totalTrials":69,"cells":321},"moxifloxacin per IV",{"EARLY_PHASE1":322,"PHASE1":324,"PHASE2":326,"PHASE3":328,"PHASE4":330,"NA":344},{"trials":323,"activeCount":73},[],{"trials":325,"activeCount":73},[],{"trials":327,"activeCount":73},[],{"trials":329,"activeCount":73},[],{"trials":331,"activeCount":73},[332],{"nctId":333,"briefTitle":334,"status":219,"phases":335,"primaryCompletion":336,"completion":336,"start":337,"enrollment":338,"conditions":339,"interventions":342},"NCT01130922","Pharmacokinetic Evaluation of Moxifloxacin Administered Intravenously and Orally in Healthy Volunteers Who Have Had a Gastric Bypass",[65],"2010-06","2010-03",12,[340,341],"Gastric Bypass","Body Weight",[320,343],"moxifloxacin per os",{"trials":345,"activeCount":73},[],{"intervention":343,"totalTrials":69,"cells":347},{"EARLY_PHASE1":348,"PHASE1":350,"PHASE2":352,"PHASE3":354,"PHASE4":356,"NA":362},{"trials":349,"activeCount":73},[],{"trials":351,"activeCount":73},[],{"trials":353,"activeCount":73},[],{"trials":355,"activeCount":73},[],{"trials":357,"activeCount":73},[358],{"nctId":333,"briefTitle":334,"status":219,"phases":359,"primaryCompletion":336,"completion":336,"start":337,"enrollment":338,"conditions":360,"interventions":361},[65],[340,341],[320,343],{"trials":363,"activeCount":73},[],{"intervention":365,"totalTrials":69,"cells":366},"Albendazole, 2 x 400mg",{"EARLY_PHASE1":367,"PHASE1":369,"PHASE2":371,"PHASE3":373,"PHASE4":375,"NA":392},{"trials":368,"activeCount":73},[],{"trials":370,"activeCount":73},[],{"trials":372,"activeCount":73},[],{"trials":374,"activeCount":73},[],{"trials":376,"activeCount":73},[377],{"nctId":378,"briefTitle":379,"status":219,"phases":380,"primaryCompletion":381,"completion":382,"start":383,"enrollment":384,"conditions":385,"interventions":387},"NCT01327469","The Efficacy of Five Anthelmintic Regimes Against Trichuris Trichiura Infections in Schoolchildren in Jimma, Ethiopia",[65],"2011-02","2011-03","2010-12",2250,[386],"Infection by Trichuris Trichiura",[365,388,389,390,391],"Albendazole 400mg","Mebendazole 500mg","Mebendazole 2 x 500mg","Pyrantel-oxantel + mebendazole",{"trials":393,"activeCount":73},[],{"intervention":388,"totalTrials":69,"cells":395},{"EARLY_PHASE1":396,"PHASE1":398,"PHASE2":400,"PHASE3":402,"PHASE4":404,"NA":410},{"trials":397,"activeCount":73},[],{"trials":399,"activeCount":73},[],{"trials":401,"activeCount":73},[],{"trials":403,"activeCount":73},[],{"trials":405,"activeCount":73},[406],{"nctId":378,"briefTitle":379,"status":219,"phases":407,"primaryCompletion":381,"completion":382,"start":383,"enrollment":384,"conditions":408,"interventions":409},[65],[386],[365,388,389,390,391],{"trials":411,"activeCount":73},[],{"intervention":389,"totalTrials":69,"cells":413},{"EARLY_PHASE1":414,"PHASE1":416,"PHASE2":418,"PHASE3":420,"PHASE4":422,"NA":428},{"trials":415,"activeCount":73},[],{"trials":417,"activeCount":73},[],{"trials":419,"activeCount":73},[],{"trials":421,"activeCount":73},[],{"trials":423,"activeCount":73},[424],{"nctId":378,"briefTitle":379,"status":219,"phases":425,"primaryCompletion":381,"completion":382,"start":383,"enrollment":384,"conditions":426,"interventions":427},[65],[386],[365,388,389,390,391],{"trials":429,"activeCount":73},[],{"intervention":390,"totalTrials":69,"cells":431},{"EARLY_PHASE1":432,"PHASE1":434,"PHASE2":436,"PHASE3":438,"PHASE4":440,"NA":446},{"trials":433,"activeCount":73},[],{"trials":435,"activeCount":73},[],{"trials":437,"activeCount":73},[],{"trials":439,"activeCount":73},[],{"trials":441,"activeCount":73},[442],{"nctId":378,"briefTitle":379,"status":219,"phases":443,"primaryCompletion":381,"completion":382,"start":383,"enrollment":384,"conditions":444,"interventions":445},[65],[386],[365,388,389,390,391],{"trials":447,"activeCount":73},[],{"intervention":391,"totalTrials":69,"cells":449},{"EARLY_PHASE1":450,"PHASE1":452,"PHASE2":454,"PHASE3":456,"PHASE4":458,"NA":464},{"trials":451,"activeCount":73},[],{"trials":453,"activeCount":73},[],{"trials":455,"activeCount":73},[],{"trials":457,"activeCount":73},[],{"trials":459,"activeCount":73},[460],{"nctId":378,"briefTitle":379,"status":219,"phases":461,"primaryCompletion":381,"completion":382,"start":383,"enrollment":384,"conditions":462,"interventions":463},[65],[386],[365,388,389,390,391],{"trials":465,"activeCount":73},[],{"intervention":467,"totalTrials":69,"cells":468},"lisinopril, ACE-inhibitor",{"EARLY_PHASE1":469,"PHASE1":471,"PHASE2":473,"PHASE3":475,"PHASE4":477,"NA":491},{"trials":470,"activeCount":73},[],{"trials":472,"activeCount":73},[],{"trials":474,"activeCount":73},[],{"trials":476,"activeCount":73},[],{"trials":478,"activeCount":73},[479],{"nctId":480,"briefTitle":481,"status":219,"phases":482,"primaryCompletion":483,"completion":484,"start":485,"enrollment":486,"conditions":487,"interventions":490},"NCT02184858","Dose Titration of Lisinopril in Children Aged 1 to 18 Years With Primary or Secondary Hypertension",[65],"2017-05-08","2018-09-17","2014-06-25",13,[488,489],"Primary Hypertension","Secondary Hypertension",[467],{"trials":492,"activeCount":73},[],{"intervention":494,"totalTrials":69,"cells":495},"Linezolid",{"EARLY_PHASE1":496,"PHASE1":498,"PHASE2":500,"PHASE3":502,"PHASE4":504,"NA":516},{"trials":497,"activeCount":73},[],{"trials":499,"activeCount":73},[],{"trials":501,"activeCount":73},[],{"trials":503,"activeCount":73},[],{"trials":505,"activeCount":73},[506],{"nctId":507,"briefTitle":508,"status":219,"phases":509,"primaryCompletion":510,"completion":510,"start":511,"enrollment":512,"conditions":513,"interventions":515},"NCT01805284","Pharmacokinetic and Pharmacodynamic Evaluation of Linezolid Administered Intravenously in MRSA-positive, Morbidly Obese Patients With Pneumonia",[65],"2016-09-30","2013-02",15,[514],"Pneumonia",[494],{"trials":517,"activeCount":73},[],{"intervention":519,"totalTrials":69,"cells":520},"Albendazole",{"EARLY_PHASE1":521,"PHASE1":523,"PHASE2":525,"PHASE3":527,"PHASE4":529,"NA":541},{"trials":522,"activeCount":73},[],{"trials":524,"activeCount":73},[],{"trials":526,"activeCount":73},[],{"trials":528,"activeCount":73},[],{"trials":530,"activeCount":73},[531],{"nctId":532,"briefTitle":533,"status":219,"phases":534,"primaryCompletion":535,"completion":337,"start":536,"enrollment":537,"conditions":538,"interventions":540},"NCT01087099","A Multinational Trial of the Efficacy of Albendazole Against Soil-transmitted Nematode Infections in Children",[65],"2009-12","2009-01",1750,[539],"Infections With Soil-Transmitted Helminths (STH)",[519],{"trials":542,"activeCount":73},[],{"intervention":544,"totalTrials":69,"cells":545},"Mebendazole",{"EARLY_PHASE1":546,"PHASE1":548,"PHASE2":550,"PHASE3":552,"PHASE4":554,"NA":572},{"trials":547,"activeCount":73},[],{"trials":549,"activeCount":73},[],{"trials":551,"activeCount":73},[],{"trials":553,"activeCount":73},[],{"trials":555,"activeCount":73},[556],{"nctId":557,"briefTitle":558,"status":219,"phases":559,"primaryCompletion":560,"completion":560,"start":561,"enrollment":86,"conditions":562,"interventions":571},"NCT01379326","Monitoring the Efficacy of Anthelmintics for the Treatment of Soil Transmitted Helminths P2",[65],"2012-12","2011-12",[563,564,565,566,567,568,569,570],"Ascaris Lumbricoides","Ascaris Suum","Trichuris Trichiura","Trichuris Vulpis","Ancylostoma Duodenal","Ancylostoma Caninum","Ancylostoma Ceylanicum","Necator Americanus",[544],{"trials":573,"activeCount":73},[],{"intervention":575,"totalTrials":69,"cells":576},"Oxytocin",{"EARLY_PHASE1":577,"PHASE1":579,"PHASE2":581,"PHASE3":583,"PHASE4":594,"NA":596},{"trials":578,"activeCount":73},[],{"trials":580,"activeCount":73},[],{"trials":582,"activeCount":73},[],{"trials":584,"activeCount":73},[585],{"nctId":586,"briefTitle":587,"status":219,"phases":588,"primaryCompletion":560,"completion":560,"start":589,"enrollment":590,"conditions":591,"interventions":592},"NCT01767025","The Influence of Oxytocin on Automatic Imitation Behaviour in Healthy Adults",[64],"2012-11",60,[18],[575,593],"Sea water",{"trials":595,"activeCount":73},[],{"trials":597,"activeCount":73},[],{"intervention":593,"totalTrials":69,"cells":599},{"EARLY_PHASE1":600,"PHASE1":602,"PHASE2":604,"PHASE3":606,"PHASE4":612,"NA":614},{"trials":601,"activeCount":73},[],{"trials":603,"activeCount":73},[],{"trials":605,"activeCount":73},[],{"trials":607,"activeCount":73},[608],{"nctId":586,"briefTitle":587,"status":219,"phases":609,"primaryCompletion":560,"completion":560,"start":589,"enrollment":590,"conditions":610,"interventions":611},[64],[18],[575,593],{"trials":613,"activeCount":73},[],{"trials":615,"activeCount":73},[],{"intervention":617,"totalTrials":69,"cells":618},"intravenous administration of levofloxacin",{"EARLY_PHASE1":619,"PHASE1":621,"PHASE2":623,"PHASE3":625,"PHASE4":636,"NA":638},{"trials":620,"activeCount":73},[],{"trials":622,"activeCount":73},[],{"trials":624,"activeCount":73},[],{"trials":626,"activeCount":73},[627],{"nctId":628,"briefTitle":629,"status":219,"phases":630,"primaryCompletion":631,"completion":631,"start":632,"enrollment":16,"conditions":633,"interventions":635},"NCT01109823","Pharmacokinetic Evaluation of Fluoroquinolone Antibiotics Administered Intravenously in Intensive Care Patients With Normal Renal Function and With Renal Hyperfiltration",[64],"2013-12-01","2010-05-19",[634],"Infection",[617],{"trials":637,"activeCount":73},[],{"trials":639,"activeCount":73},[],{"intervention":641,"totalTrials":69,"cells":642},"Golimumab",{"EARLY_PHASE1":643,"PHASE1":645,"PHASE2":647,"PHASE3":649,"PHASE4":661,"NA":663},{"trials":644,"activeCount":73},[],{"trials":646,"activeCount":73},[],{"trials":648,"activeCount":73},[],{"trials":650,"activeCount":73},[651],{"nctId":652,"briefTitle":653,"status":219,"phases":654,"primaryCompletion":655,"completion":655,"start":656,"enrollment":657,"conditions":658,"interventions":660},"NCT03270501","Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation",[64],"2023-12-14","2017-11-08",64,[659],"Axial Spondyloarthritis",[641],{"trials":662,"activeCount":73},[],{"trials":664,"activeCount":73},[],{"intervention":666,"totalTrials":69,"cells":667},"LDX.",{"EARLY_PHASE1":668,"PHASE1":670,"PHASE2":672,"PHASE3":674,"PHASE4":686,"NA":688},{"trials":669,"activeCount":73},[],{"trials":671,"activeCount":73},[],{"trials":673,"activeCount":73},[],{"trials":675,"activeCount":73},[676],{"nctId":677,"briefTitle":678,"status":679,"phases":680,"primaryCompletion":681,"completion":681,"start":681,"enrollment":73,"conditions":682,"interventions":684},"NCT01913912","Event Rate and Effects of Stimulants in ADHD","WITHDRAWN",[64],"2014-01",[683],"Attention Deficit Hyperactivity Disorder",[666,685],"sugar pill",{"trials":687,"activeCount":73},[],{"trials":689,"activeCount":73},[],{"intervention":685,"totalTrials":69,"cells":691},{"EARLY_PHASE1":692,"PHASE1":694,"PHASE2":696,"PHASE3":698,"PHASE4":704,"NA":706},{"trials":693,"activeCount":73},[],{"trials":695,"activeCount":73},[],{"trials":697,"activeCount":73},[],{"trials":699,"activeCount":73},[700],{"nctId":677,"briefTitle":678,"status":679,"phases":701,"primaryCompletion":681,"completion":681,"start":681,"enrollment":73,"conditions":702,"interventions":703},[64],[683],[666,685],{"trials":705,"activeCount":73},[],{"trials":707,"activeCount":73},[],{"intervention":709,"totalTrials":69,"cells":710},"Biodentine pulpotomy",{"EARLY_PHASE1":711,"PHASE1":713,"PHASE2":715,"PHASE3":717,"PHASE4":732,"NA":734},{"trials":712,"activeCount":73},[],{"trials":714,"activeCount":73},[],{"trials":716,"activeCount":73},[],{"trials":718,"activeCount":73},[719],{"nctId":720,"briefTitle":721,"status":219,"phases":722,"primaryCompletion":723,"completion":724,"start":725,"enrollment":726,"conditions":727,"interventions":729},"NCT01733420","Biodentine Versus White MTA Pulpotomy",[64],"2015-11","2016-02","2011-10-04",120,[728],"Extensive Decay in Primary Molars",[709,730,731],"White MTA pulpotomy","Tempophore pulpotomy",{"trials":733,"activeCount":73},[],{"trials":735,"activeCount":73},[],{"intervention":730,"totalTrials":69,"cells":737},{"EARLY_PHASE1":738,"PHASE1":740,"PHASE2":742,"PHASE3":744,"PHASE4":750,"NA":752},{"trials":739,"activeCount":73},[],{"trials":741,"activeCount":73},[],{"trials":743,"activeCount":73},[],{"trials":745,"activeCount":73},[746],{"nctId":720,"briefTitle":721,"status":219,"phases":747,"primaryCompletion":723,"completion":724,"start":725,"enrollment":726,"conditions":748,"interventions":749},[64],[728],[709,730,731],{"trials":751,"activeCount":73},[],{"trials":753,"activeCount":73},[],{"intervention":731,"totalTrials":69,"cells":755},{"EARLY_PHASE1":756,"PHASE1":758,"PHASE2":760,"PHASE3":762,"PHASE4":768,"NA":770},{"trials":757,"activeCount":73},[],{"trials":759,"activeCount":73},[],{"trials":761,"activeCount":73},[],{"trials":763,"activeCount":73},[764],{"nctId":720,"briefTitle":721,"status":219,"phases":765,"primaryCompletion":723,"completion":724,"start":725,"enrollment":726,"conditions":766,"interventions":767},[64],[728],[709,730,731],{"trials":769,"activeCount":73},[],{"trials":771,"activeCount":73},[],{"intervention":773,"totalTrials":69,"cells":774},"Bacterial spray",{"EARLY_PHASE1":775,"PHASE1":777,"PHASE2":779,"PHASE3":791,"PHASE4":793,"NA":795},{"trials":776,"activeCount":73},[],{"trials":778,"activeCount":73},[],{"trials":780,"activeCount":73},[781],{"nctId":782,"briefTitle":783,"status":219,"phases":784,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":788,"interventions":790},"NCT03967470","Bacteriotherapy to Improve Underarm Odor",[63],"2022-12-30","2018-10-01",67,[789],"Bromhidrosis",[773],{"trials":792,"activeCount":73},[],{"trials":794,"activeCount":73},[],{"trials":796,"activeCount":73},[],{"intervention":798,"totalTrials":69,"cells":799},"Administration of quinine sulphate taste-masked pellets",{"EARLY_PHASE1":800,"PHASE1":802,"PHASE2":804,"PHASE3":816,"PHASE4":818,"NA":820},{"trials":801,"activeCount":73},[],{"trials":803,"activeCount":73},[],{"trials":805,"activeCount":73},[806],{"nctId":807,"briefTitle":808,"status":219,"phases":809,"primaryCompletion":810,"completion":810,"start":811,"enrollment":812,"conditions":813,"interventions":815},"NCT00329134","Investigation of the Efficacy of Quinine Sulphate Administered Via Taste-Masked Pellets to Children With Falciparum Malaria",[63],"2007-05","2006-07",56,[814],"Malaria",[798],{"trials":817,"activeCount":73},[],{"trials":819,"activeCount":73},[],{"trials":821,"activeCount":73},[],{"intervention":823,"totalTrials":69,"cells":824},"Administration of ivermectin or permethrin",{"EARLY_PHASE1":825,"PHASE1":827,"PHASE2":829,"PHASE3":841,"PHASE4":843,"NA":845},{"trials":826,"activeCount":73},[],{"trials":828,"activeCount":73},[],{"trials":830,"activeCount":73},[831],{"nctId":832,"briefTitle":833,"status":219,"phases":834,"completion":835,"start":836,"enrollment":837,"conditions":838,"interventions":840},"NCT00262418","Comparison of the Efficacy and Safety of Ivermectin to Permethrin",[63],"2005-05","2004-07",160,[839],"Scabies",[823],{"trials":842,"activeCount":73},[],{"trials":844,"activeCount":73},[],{"trials":846,"activeCount":73},[],{"intervention":848,"totalTrials":69,"cells":849},"administration of two anti-viral drugs (lamivudine and zidovudine) from a new oral formulation",{"EARLY_PHASE1":850,"PHASE1":852,"PHASE2":862,"PHASE3":864,"PHASE4":866,"NA":868},{"trials":851,"activeCount":73},[],{"trials":853,"activeCount":73},[854],{"nctId":855,"briefTitle":856,"status":219,"phases":857,"primaryCompletion":858,"completion":535,"start":859,"enrollment":338,"conditions":860,"interventions":861},"NCT00470041","Bioavailability Study of a New Pediatric Formulation of Zidovudine\u002FLamivudine in Adult Volunteers",[62],"2009-10","2007-06",[18],[848],{"trials":863,"activeCount":73},[],{"trials":865,"activeCount":73},[],{"trials":867,"activeCount":73},[],{"trials":869,"activeCount":73},[],{"intervention":871,"totalTrials":872,"cells":873},"Microbial transplant",2,{"EARLY_PHASE1":874,"PHASE1":876,"PHASE2":878,"PHASE3":880,"PHASE4":882,"NA":884},{"trials":875,"activeCount":73},[],{"trials":877,"activeCount":73},[],{"trials":879,"activeCount":73},[],{"trials":881,"activeCount":73},[],{"trials":883,"activeCount":73},[],{"trials":885,"activeCount":73},[886,898],{"nctId":887,"briefTitle":888,"status":219,"phases":889,"primaryCompletion":890,"completion":891,"start":892,"enrollment":893,"conditions":894,"interventions":897},"NCT01581112","Microbial Community Transplantation on the Armpit\u002FFoot",[66],"2013-05","2013-06","2012-09",4,[895,896],"Heavy, Bad Body Odour From Armpit","Heavy, Bad Body Odour From Foot",[871],{"nctId":899,"briefTitle":900,"status":219,"phases":901,"primaryCompletion":902,"completion":903,"start":904,"enrollment":905,"conditions":906,"interventions":908},"NCT01944566","Microbial Community Transplantation on the Armpit.",[66],"2015-06","2015-08","2013-10",20,[907],"Heavy, Bad Odour From Armpit",[871],{"intervention":910,"totalTrials":69,"cells":911},"Benzimidazoles",{"EARLY_PHASE1":912,"PHASE1":914,"PHASE2":916,"PHASE3":918,"PHASE4":920,"NA":922},{"trials":913,"activeCount":73},[],{"trials":915,"activeCount":73},[],{"trials":917,"activeCount":73},[],{"trials":919,"activeCount":73},[],{"trials":921,"activeCount":73},[],{"trials":923,"activeCount":73},[924],{"nctId":925,"briefTitle":926,"status":219,"phases":927,"primaryCompletion":928,"completion":928,"start":929,"enrollment":930,"conditions":931,"interventions":933},"NCT04177654","Monitoring Drug Efficacy and Anthelmintic Resistance in Soil-transmitted Helminth Programs",[],"2022-12-31","2019-05-15",9457,[932],"Soil-transmitted Helminth Infections",[910],{"intervention":935,"totalTrials":69,"cells":936},"Tropicamide and phenylephrine",{"EARLY_PHASE1":937,"PHASE1":939,"PHASE2":941,"PHASE3":943,"PHASE4":945,"NA":947},{"trials":938,"activeCount":73},[],{"trials":940,"activeCount":73},[],{"trials":942,"activeCount":73},[],{"trials":944,"activeCount":73},[],{"trials":946,"activeCount":73},[],{"trials":948,"activeCount":73},[949],{"nctId":950,"briefTitle":951,"status":952,"phases":953,"primaryCompletion":954,"completion":954,"start":955,"enrollment":19,"conditions":956,"interventions":958},"NCT04040790","Performance of Rigid Gas Permeable (RGP) Scleral Contact Lenses With a Passive Artificial Iris","TERMINATED",[66],"2021-06-22","2019-09-16",[957],"Low Vision",[935],{"intervention":960,"totalTrials":69,"cells":961},"Piperacillin-tazobactam combination product",{"EARLY_PHASE1":962,"PHASE1":964,"PHASE2":966,"PHASE3":968,"PHASE4":970,"NA":972},{"trials":963,"activeCount":73},[],{"trials":965,"activeCount":73},[],{"trials":967,"activeCount":73},[],{"trials":969,"activeCount":73},[],{"trials":971,"activeCount":73},[],{"trials":973,"activeCount":73},[974],{"nctId":975,"briefTitle":976,"status":952,"phases":977,"primaryCompletion":978,"completion":978,"start":724,"enrollment":979,"conditions":980,"interventions":982},"NCT02840136","LC-MS\u002FMS Based Method Development for the Monitoring of Antibiotic Concentrations in Sputum of Cystic Fibrosis Patients",[66],"2017-09-01",40,[981],"Cystic Fibrosis",[960,983,984],"Meropenem","Ceftazidime",{"intervention":983,"totalTrials":69,"cells":986},{"EARLY_PHASE1":987,"PHASE1":989,"PHASE2":991,"PHASE3":993,"PHASE4":995,"NA":997},{"trials":988,"activeCount":73},[],{"trials":990,"activeCount":73},[],{"trials":992,"activeCount":73},[],{"trials":994,"activeCount":73},[],{"trials":996,"activeCount":73},[],{"trials":998,"activeCount":73},[999],{"nctId":975,"briefTitle":976,"status":952,"phases":1000,"primaryCompletion":978,"completion":978,"start":724,"enrollment":979,"conditions":1001,"interventions":1002},[66],[981],[960,983,984],{"intervention":984,"totalTrials":69,"cells":1004},{"EARLY_PHASE1":1005,"PHASE1":1007,"PHASE2":1009,"PHASE3":1011,"PHASE4":1013,"NA":1015},{"trials":1006,"activeCount":73},[],{"trials":1008,"activeCount":73},[],{"trials":1010,"activeCount":73},[],{"trials":1012,"activeCount":73},[],{"trials":1014,"activeCount":73},[],{"trials":1016,"activeCount":73},[1017],{"nctId":975,"briefTitle":976,"status":952,"phases":1018,"primaryCompletion":978,"completion":978,"start":724,"enrollment":979,"conditions":1019,"interventions":1020},[66],[981],[960,983,984],{"intervention":1022,"totalTrials":69,"cells":1023},"H1 blockade: H1 receptor antagonist + exercise training",{"EARLY_PHASE1":1024,"PHASE1":1026,"PHASE2":1028,"PHASE3":1030,"PHASE4":1032,"NA":1034},{"trials":1025,"activeCount":73},[],{"trials":1027,"activeCount":73},[],{"trials":1029,"activeCount":73},[],{"trials":1031,"activeCount":73},[],{"trials":1033,"activeCount":73},[],{"trials":1035,"activeCount":73},[1036],{"nctId":1037,"briefTitle":1038,"status":219,"phases":1039,"primaryCompletion":1040,"completion":1041,"start":1042,"enrollment":16,"conditions":1043,"interventions":1045},"NCT05131555","Influence of Endurance Exercise and Histamine Receptors on the Gene Expression in Skeletal Muscle",[66],"2021-12-06","2021-12-31","2021-08-16",[1044,178],"Exercise",[1022,1046],"H2 Blockade: H2 receptor antagonist + exercise training",{"intervention":1046,"totalTrials":69,"cells":1048},{"EARLY_PHASE1":1049,"PHASE1":1051,"PHASE2":1053,"PHASE3":1055,"PHASE4":1057,"NA":1059},{"trials":1050,"activeCount":73},[],{"trials":1052,"activeCount":73},[],{"trials":1054,"activeCount":73},[],{"trials":1056,"activeCount":73},[],{"trials":1058,"activeCount":73},[],{"trials":1060,"activeCount":73},[1061],{"nctId":1037,"briefTitle":1038,"status":219,"phases":1062,"primaryCompletion":1040,"completion":1041,"start":1042,"enrollment":16,"conditions":1063,"interventions":1064},[66],[1044,178],[1022,1046],{"intervention":1066,"totalTrials":69,"cells":1067},"Albendazole Pill 400mg",{"EARLY_PHASE1":1068,"PHASE1":1070,"PHASE2":1072,"PHASE3":1074,"PHASE4":1076,"NA":1078},{"trials":1069,"activeCount":73},[],{"trials":1071,"activeCount":73},[],{"trials":1073,"activeCount":73},[],{"trials":1075,"activeCount":73},[],{"trials":1077,"activeCount":73},[],{"trials":1079,"activeCount":73},[1080],{"nctId":1081,"briefTitle":1082,"status":219,"phases":1083,"primaryCompletion":1084,"completion":1085,"start":1086,"enrollment":198,"conditions":1087,"interventions":1088},"NCT03465488","Validating Egg-based Diagnostics and Molecular Markers for the Spread of Anthelmintic Resistance",[66],"2018-01-01","2019-09-01","2016-08-15",[932],[1066],{"intervention":1090,"totalTrials":69,"cells":1091},"albendazole BENDEX",{"EARLY_PHASE1":1092,"PHASE1":1094,"PHASE2":1096,"PHASE3":1098,"PHASE4":1100,"NA":1102},{"trials":1093,"activeCount":73},[],{"trials":1095,"activeCount":73},[],{"trials":1097,"activeCount":73},[],{"trials":1099,"activeCount":73},[],{"trials":1101,"activeCount":73},[],{"trials":1103,"activeCount":73},[1104],{"nctId":1105,"briefTitle":1106,"status":219,"phases":1107,"primaryCompletion":1108,"completion":1109,"start":1110,"enrollment":1111,"conditions":1112,"interventions":1114},"NCT02420574","Assessment of Drug Efficacy of Local Albendazole",[66],"2014-04","2015-02","2014-02",679,[1113],"Helminthiasis",[1090,1115],"albendazole OVIS",{"intervention":1115,"totalTrials":69,"cells":1117},{"EARLY_PHASE1":1118,"PHASE1":1120,"PHASE2":1122,"PHASE3":1124,"PHASE4":1126,"NA":1128},{"trials":1119,"activeCount":73},[],{"trials":1121,"activeCount":73},[],{"trials":1123,"activeCount":73},[],{"trials":1125,"activeCount":73},[],{"trials":1127,"activeCount":73},[],{"trials":1129,"activeCount":73},[1130],{"nctId":1105,"briefTitle":1106,"status":219,"phases":1131,"primaryCompletion":1108,"completion":1109,"start":1110,"enrollment":1111,"conditions":1132,"interventions":1133},[66],[1113],[1090,1115],{"intervention":1135,"totalTrials":69,"cells":1136},"Fexofenadine Hydrochloride",{"EARLY_PHASE1":1137,"PHASE1":1139,"PHASE2":1141,"PHASE3":1143,"PHASE4":1145,"NA":1147},{"trials":1138,"activeCount":73},[],{"trials":1140,"activeCount":73},[],{"trials":1142,"activeCount":73},[],{"trials":1144,"activeCount":73},[],{"trials":1146,"activeCount":73},[],{"trials":1148,"activeCount":73},[1149],{"nctId":1150,"briefTitle":1151,"status":219,"phases":1152,"primaryCompletion":1153,"completion":1154,"start":1155,"enrollment":1156,"conditions":1157,"interventions":1159},"NCT04450134","Histamine H1\u002FH2 Receptors and Training Adaptations",[66],"2019-12-18","2021-04-14","2019-10-02",19,[1158,30],"Exercise Training",[1135,1160],"Famotidine",{"intervention":1160,"totalTrials":69,"cells":1162},{"EARLY_PHASE1":1163,"PHASE1":1165,"PHASE2":1167,"PHASE3":1169,"PHASE4":1171,"NA":1173},{"trials":1164,"activeCount":73},[],{"trials":1166,"activeCount":73},[],{"trials":1168,"activeCount":73},[],{"trials":1170,"activeCount":73},[],{"trials":1172,"activeCount":73},[],{"trials":1174,"activeCount":73},[1175],{"nctId":1150,"briefTitle":1151,"status":219,"phases":1176,"primaryCompletion":1153,"completion":1154,"start":1155,"enrollment":1156,"conditions":1177,"interventions":1178},[66],[1158,30],[1135,1160]]